Bayer Takes On 2 More Generics Makers Over Yasmin

Law360, New York (April 21, 2008, 12:00 AM EDT) -- German pharmaceutical company Bayer AG has sued Watson Pharmaceuticals Inc. and Novartis AG unit Sandoz Inc., seeking to prevent them from marketing a generic version of the oral contraceptive Yasmin.

In a complaint filed Friday with the U.S. District Court for the Southern District of New York, Bayer alleges that Watson and Sandoz infringed one of its patents by filing abbreviated new drug applications for drospirenone and ethinyl estradiol tablets.

Drospirenone and ethinyl estradiol are the active ingredients in Yasmin.

Watson, a Corona, Calif.-based specialty pharmaceutical...
To view the full article, register now.